A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentIsavuconazole: A New Option for the Management of Invasive Fungal Infections.Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy AdultsIsavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Antifungal agents and liver toxicity: a complex interaction.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: is there a need for a new antifungal?A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
P2860
Q26740837-D32D1445-FB9B-440D-8F76-0BCC09E809D5Q28082019-B3E9889D-56D0-44CB-B377-AFCAED854549Q34474946-1C621421-8D00-4F46-999B-E512A0FB8039Q36439061-ADB36AA7-85C9-43E0-886A-181798C4A828Q37119937-2EA693CF-41BE-4368-9A51-E74980C042B0Q37631935-E8187C4D-083F-4321-AE70-88ADCCA73C65Q38436002-4145917E-4961-4693-98DF-CA8521F8D893Q38534865-66D15B91-CFF2-4F15-8572-9E769E9E4B69Q38644817-117964A6-598D-47F3-A5ED-C5DC4F465F2BQ38738090-426B11C4-178F-432F-A4A5-3B20B0D84228Q38858839-04E2E02C-F439-41D2-9CC3-6FD250B6259CQ38939506-10F7E52E-4EBB-4F76-AA72-5F8968EB021BQ40273512-C46A6D6A-60EF-4461-BB8E-15284532F384Q47660181-A964DEAA-9DFE-43C1-B669-80DCB3E2CBECQ47697145-AA3C77B0-1942-4836-AF8D-8EB299AB51CCQ54214603-FDA568C2-41C8-4989-90C3-6750F8DCC97B
P2860
A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
A phase 2, randomized, double- ...... licated esophageal candidiasis
@ast
A phase 2, randomized, double- ...... licated esophageal candidiasis
@en
type
label
A phase 2, randomized, double- ...... licated esophageal candidiasis
@ast
A phase 2, randomized, double- ...... licated esophageal candidiasis
@en
prefLabel
A phase 2, randomized, double- ...... licated esophageal candidiasis
@ast
A phase 2, randomized, double- ...... licated esophageal candidiasis
@en
P2093
P2860
P921
P356
P1476
A phase 2, randomized, double- ...... licated esophageal candidiasis
@en
P2093
A-H Schmitt-Hoffmann
M Ghannoum
P2860
P304
P356
10.1128/AAC.04586-14
P407
P577
2015-01-05T00:00:00Z